Bioengineering strategies to optimize STING agonist therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: interferon and immune responses · Viral Infections and Vectors · vaccines and immunoinformatics approaches
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Amarante-Mendes, G. P. et al. Pattern recognition receptors and the host cell death molecular machinery. Front. Immunol. 9, 2379 (2018).10.3389/fimmu.2018.02379 ↗
2. Paludan, S. R. & Bowie, A. G. Immune sensing of DNA. Immunity 38, 870–880 (2013).10.1016/j.immuni.2013.05.004 ↗
3. Jiang, M. et al. cGAS-STING, an important pathway in cancer immunotherapy. J. Hematol. Oncol. 13, 81 (2020).10.1186/s13045-020-00916-z ↗
4. Flood, B. A., Higgs, E. F., Li, S., Luke, J. J. & Gajewski, T. F. STING pathway agonism as a cancer therapeutic. Immunol. Rev. 290, 24–38 (2019).10.1111/imr.12765 ↗
5. Kwon, J. & Bakhoum, S. F. The cytosolic DNA-sensing cGAS–STING pathway in cancer. Cancer Discov. 10, 26–39 (2020).10.1158/2159-8290.CD-19-0761 ↗
6. Civril, F. et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature 498, 332–337 (2013).10.1038/nature12305 ↗
7. Kranzusch, P. J., Lee, A. S., Berger, J. M. & Doudna, J. A. Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. Cell Rep. 3, 1362–1368 (2013).10.1016/j.celrep.2013.05.008 ↗
8. Li, X. et al. Cyclic GMP-AMP synthase is activated by double-stranded DNA-induced oligomerization. Immunity 39, 1019–1031 (2013).10.1016/j.immuni.2013.10.019 ↗
9. Zhang, X. et al. The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop. Cell Rep. 6, 421–430 (2014).10.1016/j.celrep.2014.01.003 ↗
10. Xie, W. et al. Human cGAS catalytic domain has an additional DNA-binding interface that enhances enzymatic activity and liquid-phase condensation. Proc. Natl Acad. Sci. USA 116, 11946–11955 (2019).10.1073/pnas.1905013116 ↗
11. DeFilippis, V. R. et al. Interferon regulatory factor 3 is necessary for induction of antiviral genes during human cytomegalovirus infection. J. Virol. 80, 1032–1037 (2006).10.1128/JVI.80.2.1032-1037.2006 ↗
12. Wu, J., Dobbs, N., Yang, K. & Yan, N. Interferon-independent activities of mammalian STING mediate antiviral response and tumor immune evasion. Immunity 53, 115–126.e5 (2020).10.1016/j.immuni.2020.06.009 ↗
13. Liu, T., Zhang, L., Joo, D. & Sun, S.-C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2, 17023 (2017).10.1038/sigtrans.2017.23 ↗
14. Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788–792 (2009).10.1038/nature08476 ↗
15. Cao, X. et al. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat. Commun. 12, 5866 (2021).10.1038/s41467-021-26112-2 ↗
16. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405–414 (2015).10.1038/nri3845 ↗
17. Kuka, M., De Giovanni, M. & Iannacone, M. The role of type I interferons in CD4+ T cell differentiation. Immunol. Lett. 215, 19–23 (2019).10.1016/j.imlet.2019.01.013 ↗
18. Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638–652 (2014).10.1016/j.ccell.2014.09.007 ↗
19. Schiavoni, G., Mattei, F. & Gabriele, L. Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response. Front. Immunol. 4, 483 (2013).10.3389/fimmu.2013.00483 ↗
20. Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015).10.1038/nri3921 ↗
21. Kennedy, R. B. et al. Polymorphisms in STING affect human innate immune responses to poxviruses. Front. Immunol. https://doi.org/10.3389/fimmu.2020.567348 (2020).10.3389/fimmu.2020.567348 ↗
22. Lohinai, Z. et al. Loss of STING expression is prognostic in non-small cell lung cancer. J. Surg. Oncol. 125, 1042–1052 (2022).10.1002/jso.26804 ↗
23. Lee, K. M. et al. Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer. Cancer Immunol. Res. 10, 829–843 (2022).10.1158/2326-6066.CIR-21-0826 ↗
24. Low, J. T. et al. Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. Cancer Cell 40, 439–440 (2022).10.1016/j.ccell.2022.04.009 ↗
25. Xia, T., Konno, H., Ahn, J. & Barber, G. N. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 14, 282–297 (2016).10.1016/j.celrep.2015.12.029 ↗
26. Kuhl, N. et al. STING agonism turns human T cells into interferon-producing cells but impedes their functionality. EMBO Rep. 24, e55536 (2023).10.15252/embr.202255536 ↗
27. Gulen, M. F. et al. cGAS–STING drives ageing-related inflammation and neurodegeneration. Nature 620, 374–380 (2023).10.1038/s41586-023-06373-1 ↗
28. Jacquelot, N. et al. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 29, 846–861 (2019).10.1038/s41422-019-0224-x ↗
29. Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188–2205 (2023).10.1016/j.immuni.2023.09.011 ↗
30. Knelson, E. H. et al. Activation of tumor-cell STING primes NK-cell therapy. Cancer Immunol. Res. 10, 947–961 (2022).10.1158/2326-6066.CIR-22-0017 ↗
31. Lu, L. et al. STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells. Cell Rep. 42, 113108 (2023).10.1016/j.celrep.2023.113108 ↗
32. Sauer, J. D. et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 79, 688–694 (2011).10.1128/IAI.00999-10 ↗
33. Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J. Exp. Med. 208, 2005–2016 (2011).10.1084/jem.20101159 ↗
34. Lam, K. C. et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell 184, 5338–5356.e21 (2021).10.1016/j.cell.2021.09.019 ↗
35. Burnette, B. C. et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 71, 2488–2496 (2011).10.1158/0008-5472.CAN-10-2820 ↗
36. Vatner, R. E. & Janssen, E. M. STING, DCs and the link between innate and adaptive tumor immunity. Mol. Immunol. 110, 13–23 (2019).10.1016/j.molimm.2017.12.001 ↗
37. Yang, H. et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J. Clin. Investig. 129, 4350–4364 (2019).10.1172/JCI125413 ↗
38. Nicolai, C. J. et al. NK cells mediate clearance of CD8+ T cell–resistant tumors in response to STING agonists. Sci. Immunol. 5, eaaz2738 (2020).10.1126/sciimmunol.aaz2738 ↗
39. Zhang, C. X. et al. STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. Cell Death Differ. 26, 2314–2328 (2019).10.1038/s41418-019-0302-0 ↗
40. Wang, Q. et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat. Commun. 13, 3022 (2022).10.1038/s41467-022-30568-1 ↗
41. Ohkuri, T., Kosaka, A., Nagato, T. & Kobayashi, H. Effects of STING stimulation on macrophages: STING agonists polarize into “classically” or “alternatively” activated macrophages? Hum. Vaccines Immunother. 14, 285–287 (2018).10.1080/21645515.2017.1395995 ↗
42. Chen, S. et al. Macrophages in immunoregulation and therapeutics. Signal Transduct. Target. Ther. 8, 207 (2023).10.1038/s41392-023-01452-1 ↗
43. Chelvanambi, M., Fecek, R. J., Taylor, J. L. & Storkus, W. J. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J. ImmunoTher. Cancer 9, e001906 (2021).10.1136/jitc-2020-001906 ↗
44. Wang-Bishop, L. et al. STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy. Sci. Immunol. 8, eadd1153 (2023).10.1126/sciimmunol.add1153 ↗
45. Kohli, K., Pillarisetty, V. G. & Kim, T. S. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 29, 10–21 (2022).10.1038/s41417-021-00303-x ↗
46. Hoch, T. et al. Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy. Sci. Immunol. 7, eabk1692 (2022).10.1126/sciimmunol.abk1692 ↗
47. Wang, L. et al. STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells. Cell Death Dis. 15, 265 (2024).10.1038/s41419-024-06638-1 ↗
48. Berger, G. et al. STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models. Proc. Natl Acad. Sci. USA 119, e2111003119 (2022).10.1073/pnas.2111003119 ↗
49. Gulley, J. L. et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J. Natl Cancer Inst. 109, djw261 (2017).10.1093/jnci/djw261 ↗
50. Vanderlugt, C. L. & Miller, S. D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2, 85–95 (2002).10.1038/nri724 ↗
51. Walker, M. M., Crute, B. W., Cambier, J. C. & Getahun, A. B cell–intrinsic STING signaling triggers cell activation, synergizes with b cell receptor signals, and promotes antibody responses. J. Immunol. 201, 2641–2653 (2018).10.4049/jimmunol.1701405 ↗
52. Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610, 373–380 (2022).10.1038/s41586-022-05254-3 ↗
53. Salvagno, C. et al. Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nat. Cell Biol. 21, 511–521 (2019).10.1038/s41556-019-0298-1 ↗
54. Wang, C. et al. Ultrasound-responsive low-dose doxorubicin liposomes trigger mitochondrial DNA release and activate cGAS-STING-mediated antitumour immunity. Nat. Commun. 14, 3877 (2023).10.1038/s41467-023-39607-x ↗
55. Shen, J. et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 79, 311–319 (2019).10.1158/0008-5472.CAN-18-1003 ↗
56. Hayman, T. J. et al. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nat. Commun. 12, 2327 (2021).10.1038/s41467-021-22572-8 ↗
57. Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843–852 (2014).10.1016/j.immuni.2014.10.019 ↗
58. Lv, J. et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat. Med. 29, 1424–1436 (2023).10.1038/s41591-023-02369-6 ↗
59. Nakajima, S. et al. Radiation-induced remodeling of the tumor microenvironment through tumor cell-intrinsic expression of cGAS-STING in esophageal squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 115, 957–971 (2023).10.1016/j.ijrobp.2022.10.028 ↗
60. Carozza, J. A. et al. Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity. Nat. Cancer 1, 184–196 (2020).10.1038/s43018-020-0028-4 ↗
61. Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).10.1146/annurev-immunol-032712-100008 ↗
62. Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487–500 (2022).10.1038/s41590-022-01132-2 ↗
63. Carideo Cunniff, E. et al. TAK-676: a novel stimulator of interferon genes (STING) agonist promoting durable IFN-dependent antitumor immunity in preclinical studies. Cancer Res. Commun. 2, 489–502 (2022).10.1158/2767-9764.CRC-21-0161 ↗
64. Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N. & Tarsounas, M. Targeting DNA damage response pathways in cancer. Nat. Rev. Cancer 23, 78–94 (2023).10.1038/s41568-022-00535-5 ↗
65. Zhou, S. et al. Engineering cGAS-agonistic oligonucleotides as therapeutics for cancer immunotherapy. Mol. Ther. Nucleic Acids 35, 102126 (2024).10.1016/j.omtn.2024.102126 ↗
66. Liu, H. et al. Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity. Cell Rep. 42, 112275 (2023).10.1016/j.celrep.2023.112275 ↗
67. Laursen, M. F. et al. CD11c-targeted delivery of DNA to dendritic cells leads to cGAS- and STING-dependent maturation. J. Immunother. 41, 9–18 (2018).10.1097/CJI.0000000000000195 ↗
68. Wang, C. et al. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses. Immunity 48, 675–687.e7 (2018).10.1016/j.immuni.2018.03.017 ↗
69. Smith, J. A. STING, the endoplasmic reticulum, and mitochondria: is three a crowd or a conversation? Front. Immunol. 11, 611347 (2020).10.3389/fimmu.2020.611347 ↗
70. Petrasek, J. et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc. Natl Acad. Sci. USA 110, 16544–16549 (2013).10.1073/pnas.1308331110 ↗
71. McKnight, K. L. et al. Stimulator of interferon genes (STING) is an essential proviral host factor for human rhinovirus species A and C. Proc. Natl Acad. Sci. USA 117, 27598–27607 (2020).10.1073/pnas.2014940117 ↗
72. Danilchanka, O. & Mekalanos, J. J. Cyclic dinucleotides and the innate immune response. Cell 154, 962–970 (2013).10.1016/j.cell.2013.08.014 ↗
73. Ross, P. et al. Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid. Nature 325, 279–281 (1987).10.1038/325279a0 ↗
74. Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339, 826–830 (2013).10.1126/science.1229963 ↗
75. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).10.1126/science.1232458 ↗
76. Wang, H. et al. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc. Natl Acad. Sci. USA 114, 1637–1642 (2017).10.1073/pnas.1621363114 ↗
77. Guo, J. et al. Distinct dynamic and conformational features of human STING in response to 2′3′-cGAMP and c-di-GMP. ChemBioChem 20, 1838–1847 (2019).10.1002/cbic.201900051 ↗
78. Zhang, X. et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 51, 226–235 (2013).10.1016/j.molcel.2013.05.022 ↗
79. Corrales, L. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11, 1018–1030 (2015).10.1016/j.celrep.2015.04.031 ↗
80. Wang, S. et al. ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer. Proc. Natl Acad. Sci. USA 120, e2313693120 (2023).10.1073/pnas.2313693120 ↗
81. Wang, Z. & Xi, Z. Chemical evolution of cyclic dinucleotides: perspective of the analogs and their preparation. Tetrahedron 87, 132096 (2021).10.1016/j.tet.2021.132096 ↗
82. Chang, W. et al. Discovery of MK-1454: a potent cyclic dinucleotide stimulator of interferon genes agonist for the treatment of cancer. J. Med. Chem. 65, 5675–5689 (2022).10.1021/acs.jmedchem.1c02197 ↗
83. Meric-Bernstam, F. et al. Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoural STING agonist, in patients with advanced/metastatic solid tumors or lymphomas. Clin. Cancer Res. 28, 677–688 (2022).10.1158/1078-0432.CCR-21-1963 ↗
84. Calvo, E. et al. 1030P phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors. Ann. Oncol. 34, S626 (2023).
85. Kim, D. S. et al. E7766, a macrocycle-bridged stimulator of interferon genes (STING) agonist with potent pan-genotypic activity. ChemMedChem 16, 1740–1743 (2021).
86. Luke, J. J. et al. Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors. J. ImmunoTher. Cancer 13, e010511 (2025).10.1136/jitc-2024-010511 ↗
87. Vyskocil, S. et al. Identification of novel carbocyclic pyrimidine cyclic dinucleotide STING agonists for antitumor immunotherapy using systemic intravenous route. J. Med. Chem. 64, 6902–6923 (2021).10.1021/acs.jmedchem.1c00374 ↗
88. Diamond, J. R. et al. Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors. J. Clin. Oncol. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS2690 (2022).10.1200/JCO.2022.40.16_suppl.TPS2690 ↗
89. Bukhalid, R. A. et al. XMT-2056, a HER2-directed STING agonist antibody–drug conjugate, induces innate antitumor immune responses by acting on cancer cells and tumor-resident immune cells. Clin. Cancer Res. 31, 1766–1782 (2025).10.1158/1078-0432.CCR-24-2449 ↗
90. Soomer-James, J., Damelin, M. & Malli, N. Abstract 4423: XMT-2056, a HER2-targeted STING agonist antibody-drug conjugate, exhibits ADCC function that synergizes with STING pathway activation and contributes to anti-tumor responses. Cancer Res. https://doi.org/10.1158/1538-7445.AM2023-4423 (2023).10.1158/1538-7445.AM2023-4423 ↗
91. Janku, F. et al. A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors. J. Clin. Oncol. https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS3162 (2020).10.1200/JCO.2020.38.15_suppl.TPS3162 ↗
92. Ramanjulu, J. M. et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 564, 439–443 (2018).10.1038/s41586-018-0705-y ↗
93. Kelly, C. M. et al. Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors. J. Clin. Oncol. https://doi.org/10.1200/JCO.2023.41.16_suppl.9120 (2024).10.1200/JCO.2023.41.16_suppl.9120 ↗
94. Liu, B. et al. Human STING is a proton channel. Science 381, 508–514 (2023).10.1126/science.adf8974 ↗
95. Chin, E. N. et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science 369, 993–999 (2020).10.1126/science.abb4255 ↗
96. Pan, B.-S. et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 369, eaba6098 (2020).10.1126/science.aba6098 ↗
97. Allen, B. K. et al. Design of a systemic small molecule clinical STING agonist using physics-based simulations and artificial intelligence. Preprint at bioRxiv https://doi.org/10.1101/2022.05.23.493001 (2022).10.1101/2022.05.23.493001 ↗
98. Caldwell, S. E., Janosko, C. P. & Deiters, A. Development of a light-activated STING agonist. Org. Biomol. Chem. 22, 302–308 (2024).10.1039/D3OB01578E ↗
99. Huayamares, S. G., Loughrey, D., Kim, H., Dahlman, J. E. & Sorscher, E. J. Nucleic acid-based drugs for patients with solid tumours. Nat. Rev. Clin. Oncol. 21, 407–427 (2024).10.1038/s41571-024-00883-1 ↗
100. Simonsen, J. B. Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies – challenges and opportunities. J. Control. Release 370, 763–772 (2024).10.1016/j.jconrel.2024.04.022 ↗